- Affimed N.V. (NASDAQ:AFMD) has placed its AFM11 program on clinical hold following three serious adverse events (SAEs), one death in a Phase 1 ALL study and two life-threatening events in a Phase 1 NHL study.
- The SAEs occurred in patients receiving the highest dose in each of the respective studies. 33 total patients have been treated to date.
Catalyst
Slingshot members are tracking this event:
Affimed (AFMD) Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AFMD |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 08, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Afm11, Cd19, Blood Cancer
